Fauci Cautious of U.K.’s Speedy Vaccine Approval
December 4, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Eric Sagonowsky The U.K.’s monumental approval for Pfizer and BioNTech’s COVID-19 vaccine turned heads worldwide, but one of the leading voices in the U.S. pandemic response argues the country’s regulators acted too quickly. “If you go quickly and you do it superficially, people are not going to want to get vaccinated,” NIAID director Anthony Fauci told Fox News. “We have the gold standard of a regulatory approach with the FDA.” The U.K.’s Medicines and Healthcare Products Regulatory Authority (MHRA) “did not do

Read More

Feds Lay Out Ambitious Plan for Vaccine Rollout
November 20, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Arlene Weintraub With Moderna and Pfizer both reporting sky-high response rates to their COVID-19 vaccines, the pressure is on federal health officials to ensure a rapid—but smooth—rollout. Wednesday, they unveiled a detailed timeline that provides some clues about when most Americans can expect to be vaccinated. High-priority populations such as healthcare workers and nursing home residents could obtain COVID-19 vaccines in December, Department of Health and Human Services Secretary Alex Azar said in a press conference. Anthony Fauci, M.D., director of

Read More

Pfizer Could Release COVID Vaccine in Powder Form
November 13, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Fraiser Kansteiner Pfizer on Monday revealed stellar early results from its phase 3 COVID-19 vaccine trial, but the news was quickly met with concerns about access as the vaccine comes with hefty cold chain requirements. Pfizer, for its part, already has its sights set on a next-generation formula that could help resolve those storage concerns, the drugmaker’s top scientist said. The drugmaker is weighing several options for an improved vaccine that could be ready as early as 2021. “For the COVID-19

Read More